translation agency

Reuters New Media
Patient Makes Anti-HIV Immunity Cells in Enzo Trail

October 2, 2000
FARMINGDALE, N.Y. (Reuters) - Biotech company Enzo Biochem Inc. (NYSE:ENZ - news) said on Monday a patient participating in a Phase I study produced new immunity cells to combat the virus that causes AIDS web-.

The tests show that after nine-and-one-half months, Enzo- engineered cells have successfully engrafted in the patient's bone marrow and were spawning new cells designed to fight HIV.

The company said it is preparing for a Phase II trial of the HGTV-43 medicine product and has already begun negotiating with several hospitals at which broader studies would be conducted.

Enzo is compiling and analyzing data from the remaining five patients in the trial, and said that the data is highly encouraging, though limited and must await further study.